HomeBUSINESS
BUSINESS

I/O in Lung Cancer - 4: Bristol-Myers Looks to Regain Ground for Opdivo with Immunotherapy Combos
(Sep.5.2018)

Kiyoshi Hashigami, Head of Medical & Development Japan, Korea, and Taiwan, Senior Managing Executive Officer, Bristol-Myers Squibb K.K.
By Takashi Ebisawa

Ono Pharmaceutical/Bristol-Myers Squibb’s Opdivo (nivolumab) has been the leader in the checkpoint inhibitor market since it earned the world’s first approval in Japan in 2014. With archrival Keytruda (pembrolizumab) notching up breakneck growth in the lung cancer space, however, analysts now expect the Merck drug to globally outsell the I/O pioneer in FY2018. How will the Opdivo camp pursue its development going forward? Kiyoshi Hashigami, BMS’s head of medical & development Japan, Korea, and Taiwan, shares their strategies ...
(LOG IN FOR FULL STORY)

News Calendar